• Return to Headlines

Relatively Low Debt-to-Capital Ratio Detected in Shares of Epizyme Inc in the Biotechnology Industry (EPZM, ACHN, MGNX, ENTA, NLNK)

By Nick Russo

Below are the three companies in the Biotechnology industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Epizyme Inc ranks lowest with a a Debt-to-Capital ratio of 4.7%. Achillion Pharma is next with a a Debt-to-Capital ratio of 9.3%. Macrogenics Inc ranks third lowest with a a Debt-to-Capital ratio of 9.9%.

Enanta Pharmaceu follows with a a Debt-to-Capital ratio of 15.2%, and Newlink Genetics rounds out the bottom five with a a Debt-to-Capital ratio of 17.8%.

SmarTrend recommended that subscribers consider buying shares of Epizyme Inc on January 4th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $6.98. Since that recommendation, shares of Epizyme Inc have risen 65.0%. We continue to monitor Epizyme Inc for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest debt-to-capital ratio epizyme inc achillion pharma macrogenics inc enanta pharmaceu newlink genetics

Ticker(s): EPZM ACHN MGNX ENTA NLNK